Sign in

NCT03418844Active, not recruiting

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Source: ClinicalTrials.gov · Last updated 22 Sept 2025

Brief summary (registry, in English)

While they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and QoL of women in remission of rare ovarian cancer remain poorly explored. The coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic fatigue and QoL and 2) chemotherapy-related sequelae in adult patients in remission of surgery-treated TGMO or TSCS (conservative or not) supplemented with chemotherapy

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
268 (estimated)
First submitted
15 Jan 2018
Start date
7 May 2018
Primary completion date
13 Jul 2021
Lead sponsor
Centre Francois Baclesse
NCT number
NCT03418844

What you commit to

  • Study type: Interventional
  • Planned participants: 268
  • From 7 May 2018 to the primary completion date, 13 Jul 2021
  • 19 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Psychiatric pathology that may disrupt the course of the study or prevent the interpretation of results;

Other

  • Pregnant or breastfeeding woman;
  • Person deprived of liberty;
  • Major subject to a legal protection measure or unable to express his consent.

Who the study is looking for

  • Age\> 18 years;
  • Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally;
  • Patient who has had surgery and chemotherapy (interest group) or only a surgery (control group);
  • Patient in remission more than 2 years after the end of the initial treatment;
  • Relapse authorized if remission more than 2 years after the end of the treatment;
  • Patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix);
  • Patient having signed his consent to participate

Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (19)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centre Paul Papin
Coordinator of this site? Confirm its status
AngersFranceUnknown status
CHU Besançon Jean MINJOZ
Coordinator of this site? Confirm its status
BesançonFranceUnknown status
Institut Bergonie
Coordinator of this site? Confirm its status
BordeauxFranceUnknown status
CH Fleyriat
Coordinator of this site? Confirm its status
Bourg-en-BresseFranceUnknown status
Centre François Baclesse
Coordinator of this site? Confirm its status
CaenFranceUnknown status
Centre Jean Perrin
Coordinator of this site? Confirm its status
Clermont-FerrandFranceUnknown status
Centre Leon Berard
Coordinator of this site? Confirm its status
LyonFranceUnknown status
Institut Paoli-Calmettes
Coordinator of this site? Confirm its status
MarseilleFranceUnknown status
Institut de Cancérologie de l'Ouest
Coordinator of this site? Confirm its status
NantesFranceUnknown status
Centre Catherine de Sienne
Coordinator of this site? Confirm its status
NantesFranceUnknown status
GH Cochin Broca Hôtel-Dieu
Coordinator of this site? Confirm its status
ParisFranceUnknown status
HEGP
Coordinator of this site? Confirm its status
ParisFranceUnknown status
Institut Curie
Coordinator of this site? Confirm its status
ParisFranceUnknown status
Institut Gustave Roussy
Coordinator of this site? Confirm its status
ParisFranceUnknown status
Hôpital Diaconesses-Croix St Simon
Coordinator of this site? Confirm its status
ParisFranceUnknown status
CHU Poitiers
Coordinator of this site? Confirm its status
PoitiersFranceUnknown status
Institut Jean Godinot
Coordinator of this site? Confirm its status
ReimsFranceUnknown status
Institut Rennais de Cancérologie
Coordinator of this site? Confirm its status
RennesFranceUnknown status
CHRU Stasbourg Hôpital Civil
Coordinator of this site? Confirm its status
StrasbourgFranceUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.